C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 10, 2021, by C4 Therapeutics, Inc. (Nasdaq: CCCC). The filing primarily serves to announce the election of a new director and to reference the press release issued on March 11, 2021, regarding financial results for the fourth quarter and fiscal year ended December 31, 2020.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Governance
- Director Election: The Board elected Glenn Dubin as a director, effective the first business day after the filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
- Compensation: Mr. Dubin was granted stock options to purchase up to 41,200 shares of common stock. Vesting occurs over three years (one-third on the first anniversary, remainder quarterly).
- Related Party Transactions: Funds affiliated with Mr. Dubin (Commodore Capital Master LP and DF Investment Partners LLC) previously purchased Series B preferred stock in June 2020 and common stock in the October 2020 IPO.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. These details are located in the referenced press release (Exhibit 99.1). The filing includes standard legal disclaimers stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) in the March 11, 2021 press release (Exhibit 99.1) as they are not detailed in this 8-K text.
- Confirm the effective date of Glenn Dubin's directorship, which is tied to the filing of the 2020 Form 10-K.
- Review the vesting schedule and terms of the 41,200 stock options granted to Mr. Dubin.
- Assess the extent of Mr. Dubin's affiliated funds' holdings in the company following the Series B financing and IPO conversions.